GFM
IMRX icon

GF Fund Management’s Immuneering IMRX Stock Holding History

GF Fund Management’s Portfolio IMRX Stock Details IMRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$6.69K Sell
1,341
-101
-7% -$511 ﹤0.01% 559
2026
Q1 		$7.6K Buy
1,442
+174
+14% +$892 ﹤0.01% 581
2025
Q4 		$8.34K Buy
+1,268
New +$8.14K ﹤0.01% 593

Other funds holding IMRX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
S
Sanofi Paris, France $534M AUM 205.96% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
DA
DCF Advisers Greenwich, Connecticut $566M AUM 197.74% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return
Connor, Clark & Lunn Investment Management (CC&L)
Connor, Clark & Lunn Investment Management (CC&L) Vancouver, British Columbia, Canada $52.8B AUM 58.98% 1-Year Est. Return

GF Fund Management's IMRX Position: Q2 2026 in Review

GF Fund Management reduced its Immuneering (IMRX) stake by 7% in Q2 2026, selling an estimated $511 and leaving 1,341 shares worth $6.69K. The position accounts for ﹤0.01% of the portfolio, ranked #559.

GF Fund Management first reported a position in IMRX in Q4 2025 and has held it in 3 quarters since. The position peaked at $8.34K in Q4 2025. 112 funds tracked by Wall St. Rank hold IMRX as of Q2 2026.

  • GF Fund Management held 1,341 shares of Immuneering worth $6.69K as of Q2 2026.
  • GF Fund Management sold 101 Immuneering shares in Q2 2026, an estimated $511.
  • Immuneering made up ﹤0.01% of GF Fund Management's portfolio in Q2 2026, its #559 holding.
  • GF Fund Management first reported a position in Immuneering in Q4 2025 and has held it in 3 quarters since.
  • GF Fund Management's Immuneering position peaked at $8.34K in Q4 2025.
  • 112 funds tracked by Wall St. Rank held Immuneering as of Q2 2026.

Based on GF Fund Management's 13F filing for Q2 2026, filed 7 Aug 2026.